HOME >> BIOLOGY >> NEWS
Scientists at TSRI receive $9.6 million to develop treatment for common cause of vision loss

A group of researchers at The Scripps Research Institute (TSRI), who recently discovered a potent inhibitor of angiogenesis, a process implicated in cancer and one of the leading causes of blindness in the United States, have been awarded a five-year, $9.6 million grant from the National Eye Institute to study this inhibitor further and develop ways to use it in patients with neovascular eye disease.

"What we would like to do is to take a basic science laboratory observation as close to the clinic as we can," says Martin Friedlander, M.D., Ph.D., the principal investigator on the grant, an associate professor in TSRI's Department of Cell Biology and Chief of the Retina Service in the Division of Ophthalmology, Department of Surgery at Scripps Clinic.

The vast majority of diseases that cause catastrophic vision loss do so as a result of abnormal angiogenesis, the uncontrolled growth of new blood vessels in the back of the eye. The leading cause of vision loss in patients who are above the age of 65 is macular degeneration. Twelve to fifteen million people in this country alone have macular degeneration, and 10 to 15 percent of them will suffer acute loss of vision.

In patients under the age of 65, the leading cause of vision loss is due to a complication of diabetes known as diabetic retinopathy. Some 16 to 18 percent of the U.S. population has diabetes. Virtually every one of those patients will eventually have a form of diabetic retinopathy after 20 years and every year 40,000 of them lose vision as a result of complications from diabetes.

Both macular degeneration and diabetic retinopathy are characterized by abnormal angiogenesis. In the case of macular degeneration, new blood vessels grow under the retina. In diabetic retinopathy, abnormal vessels grow on top of the retina. The effect is much the same; the vessels interfere with normal structures or the transmission of light to the back of the eye, impeding vision.

There
'"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
22-Aug-2002


Page: 1 2 3

Related biology news :

1. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
2. Scientists sequence genome of kind of organism central to biospheres carbon cycle
3. Scientists find nanowires capable of detecting individual viruses
4. Scientists discover potential new way to control drug-resistant bacteria
5. Scientists explore genome of methane-breathing microbe
6. Scientists decipher genetic code of biothreat pathogen
7. Stuck on you: Scientists lay bare secrets of bacterial attachment proteins
8. Scientists discover proteins involved in spread of HIV-1 infection
9. Scientists fear new Ebola outbreak may explain sudden gorilla disappearance
10. Scientists reinvent DNA as template to produce organic molecules
11. Scientists visualise cellular handmaiden that restores shape to proteins

Post Your Comments:
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
(Date:12/17/2014)... December 17, 2014 Audacity, a leading ... and member of the Huntsworth Health Group, is proud ... executive team. In her role, Gonzales will serve as ... are incredibly honored to welcome a talent of Jamie’s ... CEO, Gaëtan Fraikin. “She is a proven healthcare innovation ...
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat Pharma, ... 2 study evaluating the investigational oral NK-1 receptor ... with severe, chronic itch who are unresponsive or ... including topical steroids and antihistamines. ... Visual Analog Scale (VAS) itch score from baseline, ...
(Date:12/15/2014)... Organovo Holdings, Inc. (NYSE MKT: ONVO) ... breakthrough 3D bioprinting technology,  today celebrated continued positive ... exVive3D TM Human Liver Tissue.  The product, ... release on November 18, has been recognized as ... for innovation. Most recently, on December ...
(Date:12/13/2014)... CanDiag, Inc., a University of North ... its name to OncoTab, Inc. , “The new ... are today,” said CEO and Chief Science Officer, Dr. ... breast cancer diagnostics to include imaging and therapies, and ... , Founded in 2011 by Dr. Mukherjee, an Irwin ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
Cached News: